title: Vertical transmission of human immunodeficiency virus (HIV) infection. Reactivity of maternal sera with glycoprotein 120 and 41 peptides from HIV type 1.
abstract: The observation that approximately 70% of HIV-infected pregnant women do not transmit infection vertically suggests that antibody therapy may be effective in the prevention of transmission of HIV infection from mother to child. Currently, there is an incomplete understanding of the processes involved in vertical transmission of HIV infection. The elucidation of the serological basis of maternal immunity as it relates to protection from vertical transmission is the goal of this study. We have screened 20 maternal sera from HIV+ individuals of known vertical transmission status for reactivity with 31 peptides spanning the entire envelope glycoprotein of HIV-1. Of interest was reactivity to regions outside of the V3 loop of gp120. The findings have been examined in relationship to transmission status, as well as to in vitro anti-HIV-1 biological activity. Our results indicate that lack of vertical transmission is correlated with high viral neutralization activity, but not with antisyncytial activity nor with binding to the V3 peptides examined in this study. Also, the transmission group bound to fewer gp41 peptides when compared with the nontransmission group, suggesting that immune responses to gp41 may be important in preventing transmission. These findings may provide insights into the design of passive immunotherapies.
authors.affiliation: Wistar Institute of Anatomy and Biology, Pennsylvania.
authors.forename: K E
authors.initials: KE
authors.lastname: Ugen
authors.forename: J J
authors.initials: JJ
authors.lastname: Goedert
authors.forename: J
authors.initials: J
authors.lastname: Boyer
authors.forename: Y
authors.initials: Y
authors.lastname: Refaeli
authors.forename: I
authors.initials: I
authors.lastname: Frank
authors.forename: W V
authors.initials: WV
authors.lastname: Williams
authors.forename: A
authors.initials: A
authors.lastname: Willoughby
authors.forename: S
authors.initials: S
authors.lastname: Landesman
authors.forename: H
authors.initials: H
authors.lastname: Mendez
authors.forename: A
authors.initials: A
authors.lastname: Rubinstein
mesh_terms: D000328:Adult; D000595:Amino Acid Sequence; D015331:Cohort Studies; D005260:Female; D015726:Giant Cells / Q000276:immunology; D015483:HIV Antibodies / Q000097:blood / Q000276:immunology; D015699:HIV Envelope Protein gp120 / Q000276:immunology*; D015700:HIV Envelope Protein gp41 / Q000276:immunology*; D015658:HIV Infections / Q000276:immunology / Q000635:transmission*; D015497:HIV-1 / Q000276:immunology* / Q000502:physiology; D006801:Humans; D007231:Infant, Newborn; D008969:Molecular Sequence Data; D009500:Neutralization Tests; D010446:Peptide Fragments / Q000276:immunology; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000276:immunology* / Q000382:microbiology; D011446:Prospective Studies; D014407:Tumor Cells, Cultured
chemical_list: D015483:HIV Antibodies; D015699:HIV Envelope Protein gp120; D015700:HIV Envelope Protein gp41; D010446:Peptide Fragments